A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Completed · Phase 3 · NCT05963022
Conditions: Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $1,942
- U.S. investigators named
- 4
- Sites paid
- 1
- Planned or actual enrollment
- 206
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (drug)
- Dates
- Started 2023-08-21; completion 2024-10-09
- Results posted
- Yes
The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.
From ClinicalTrials.gov, last updated 2025-10-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1,942 in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anirudh R. Nandan Student in an Organized Health Care Education/Training Program · San Francisco, CA
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Robert E. Dunn, MD Cardiac Electrophysiology · Cleveland, OH
- Zackary D. Goff, M.D. Cardiology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.